Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial

被引:59
|
作者
Goldstein, J
Silberstein, SD
Saper, JR
Elkind, AH
Smith, TR
Gallagher, RM
Battikha, JP
Hoffman, H
Baggish, J
机构
[1] San Francisco Clin Res Ctr, San Francisco Headache Clin, San Francisco, CA 94109 USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Michigan Head Pain & Neurol Inst, Ann Arbor, MI USA
[4] Elkind Headache Ctr, Mt Vernon, NY USA
[5] Ryan Headache Ctr, Chesterfield, MO USA
[6] UMDNJ, Sch Osteopath Med, Moorestown, NJ USA
[7] Bristol Myers Squibb Co, Plainsboro, NJ USA
来源
HEADACHE | 2005年 / 45卷 / 08期
关键词
migraine; early treatment; clinical trial; sumatriptan; nonprescription medication; caffeine;
D O I
10.1111/j.1526-4610.2005.05177.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective. - To address the need for a rigorous, direct comparison of prescription and over- the-counter ( OTC) migraine drugs and to expand the database on early treatment of migraine. Background. - Most people who experience migraine use OTC medications to treat their symptoms, but no head-to-head clinical trials comparing these agents with prescription migraine therapies have been published. In addition, even though most migraineurs treat early in the attack, few studies have been conducted to reflect this treatment pattern. Methods. - We compared a combination of nonprescription migraine medication ( acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg) with a prescription migraine product ( 50 mg sumatriptan) in a randomized, controlled clinical trial in which subjects treated at the first sign of a migraine attack. Subjectswho reported vomiting during more than 20% of migraine episodes or who required bedrest during more than 50% of migraine episodes were excluded from the study. Of the 188 subjects randomized, 171 took study medication and were included in the analysis. Conclusion. - The combination of acetaminophen, aspirin, and caffeine was significantly more effective ( P > .05) than sumatriptan in the early treatment of migraine, as shown by superiority in summed pain intensity difference, pain relief, pain intensity difference, response, sustained response, relief of associated symptoms, use of rescue medication, disability relief, and global assessments of effectiveness. An additional, larger clinical trial is needed to confirm these results.
引用
收藏
页码:973 / 982
页数:10
相关论文
共 50 条
  • [31] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [32] Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study
    Lipton, Richard B.
    McGinley, James S.
    Shulman, Kenneth J.
    Wirth, R. J.
    Buse, Dawn C.
    HEADACHE, 2017, 57 (10): : 1570 - 1582
  • [33] Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials
    Winner, P
    Landy, S
    Richardson, M
    Ames, M
    CLINICAL THERAPEUTICS, 2005, 27 (11) : 1785 - 1794
  • [34] Long-term Impact of Immediate Versus Delayed Treatment of Early Glaucoma: Results From the Early Manifest Glaucoma Trial
    Heijl, Anders
    Peters, Dorothea
    Bengtsson, Boel
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 252 : 286 - 294
  • [35] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter J.
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 14 - 15
  • [36] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, Patricia
    Ailani, Jessica
    Ashina, Messoud
    Goadsby, Peter
    Lipton, Richard
    Reuter, Uwe
    Guo, Hua
    Schwefel, Brittany
    Boinpally, Ramesh
    McCusker, Emily
    Yu, Sung Yun
    Finnegan, Michelle
    Trugman, Joel
    NEUROLOGY, 2023, 100 (17)
  • [37] Characteristics of menstrually-related migraine and treatment with almotriptan: Results from the AEGIS trial
    Diamond, M. L.
    Cady, R. K.
    Finlayson, G.
    Wright, P.
    Mao, L.
    Biondi, D. M.
    Greenberg, S. J.
    HEADACHE, 2007, 47 (05): : 787 - 787
  • [38] Atogepant for the preventive treatment of chronic migraine: Results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Goadsby, P. J.
    HEADACHE, 2022, 62 (07): : 923 - 923
  • [39] Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
    Pozo-Rosich, P.
    Ailani, J.
    Ashina, M.
    Goadsby, P.
    Lipton, R.
    Reuter, U.
    Guo, H.
    Schwefel, B.
    Boinpally, R.
    McCusker, E.
    Yu, S. Yun
    Finnegan, M.
    Trugman, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [40] Metoclopramide versus sumatriptan in the treatment of migraine in the emergency department: a single-center, open-label, clusterrandomized controlled non-inferiority trial
    Funato, Yumi
    Kimura, Akio
    Matsuda, Wataru
    Uemura, Tatsuki
    Fukano, Kentaro
    Kobayashi, Kentaro
    Sasaki, Ryo
    GLOBAL HEALTH & MEDICINE, 2020, 2 (04): : 259 - 262